Therapeutic Solutions International Inc (TSOI)

[centsability4me]

JadiCells won't always be JadiCells

https://forum.therapeuticsolutionsint.com/viewtopic.php?t=268

Post by TimGDixon » Wed Jul 20, 2022 4:13 am
JadiCell is the trademark of JadiCell LLC but we are not obligated nor required to use that name and we intend to change its name and file new trademark(s), perhaps multiple based on each of these and their specific use.

05-12-2022 Inhibition and Reversion of Chronic Obstructive Pulmonary Disease (COPD) by Endothelial Cell Regeneration

https://therapeuticsolutionsint.com/hase-iii-lung-adult-stem-cell-company-announces-and-files-patent-on-leukine-induced-myeloid-derived-suppressor-cells-and-jadicell-for-treatment-of-copd/

Disclosed are means, treatment methods, and compositions of matter useful for prevention and/or reversion of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of mesenchymal stem cells and exosome thereof as a means of augmenting endogenous endothelial regeneration and/or endothelial regeneration stimulated by exogenous means. In some embodiments the invention provides administration of allogeneic mesenchymal stem cells together with autologous endothelial progenitor cells and/or mobilization of said autologous endothelial progenitor cells

03-07-2022 Treatment of Trauma Associated Cognitive Dysfunction Using Mesenchymal Stem Cell Apoptotic Bodies and Compositions Thereof

https://therapeuticsolutionsint.com/therapeutic-solutions-international-announces-apoptocyte-procedure-for-enhancing-stem-cell-activity/

Disclosed are means, treatments and compositions of matter useful for treatment of chemotherapy/radiotherapy associated cognitive dysfunction. In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse cognitive dysfunction associated with chemotherapy and/or radiation therapy. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of neuroregeneration directly or indirectly.

10-11-2021 Umbilical Cord Derived Regenerative and Immune Modulatory Stem Cell Populations

https://therapeuticsolutionsint.com/therapeutic-solutions-international-announces-initiation-of-jadicell-manufacturing-program-to-address-upcoming-fda-phase-iii-trial-and-emergency-use-requests/

The present invention provides universal donor cellular populations derived from umbilical cords possessing ability to elicit immune modulation and evoke regeneration when administered into a mammalian host. Generation of cellular products for clinical use are provided including methodologies of expansion, characterization, and means of therapeutic implementation.

10-04-2021 Reduction of Neutrophil Extracellular Trap formation by Mesenchymal Stem Cells and their Exosomes

https://therapeuticsolutionsint.com/therapeutic-solutions-international-utilizes-mesenchymal-stem-cell-exosomes-to-effectively-suppress-neutrophil-extracellular-trap-production/

Disclosed are methods of reducing lung inflammation in acute respiratory distress syndrome elicited by various factors such as COVID-19 infection by reduction of neutrophil extracellular trap formation through administration of mesenchymal stem cells and/or exosomes thereof. The invention provides means of inhibiting neutrophil release of extracellular traps by mesenchymal stem cells and/or exosomes derived from said mesenchymal stem cells. Additionally, synergies are provided between mesenchymal stem cells and/or exosomes derived from mesenchymal stem cells and agents approaches which reduce neutrophil extracellular trap formation.

09-22-2021 Stimulation of Mesenchymal Stem Cell Therapeutic Activities by T Regulatory Cells

https://therapeuticsolutionsint.com/therapeutic-solutions-international-discovers-and-files-patent-on-novel-cellular-therapy-combination-for-augmentation-of-lung-repair-in-covid-19-model/

Disclosed are novel means of enhancing mesenchymal stem cell regenerative activities including, intra alia, production from pulmonary leakage and suppression of scar tissue formation by co-administration with T regulatory cells. In some embodiments the invention provides an interaction between T regulatory cells and mesenchymal stem cells in which T regulatory cells stimulate upregulation of mesenchymal stem cell activity in a GITR dependent manner.

08-23-2021 Umbilical Cord Mesenchymal Stem Cells for Treatment of Chronic Obstructive Pulmonary Disease and Lung Degeneration

https://therapeuticsolutionsint.com/therapeutic-solutions-international-announces-positive-preclinical-results-using-jadicells-in-animal-model-of-chronic-obstructive-pulmonary-failure-copd/

The invention discloses means of treating lung degenerative diseases including chronic obstructive pulmonary disease (CODP) using umbilical cord mesenchymal stem cells such as JadiCells alone, and/or using said cells under conditions that are activated in order to endow enhanced regenerative activity. In one embodiment said activation of said mesenchymal stem cells is performed through stimulation with a toll like receptor agonist at a concentration and duration sufficient to induce a >50% increase in keratinocyte growth factor expression from said stem cells. In another embodiment the invention provides the use of JadiCells as a means of producing exosomes, wherein said exosomes possess therapeutic properties capable of reducing inflammation, fibrosis and degeneration associated with COPD, as well as stimulation of regenerative activity. In some JadiCells are activated by a treatment with Activated Protein C.

08-18-2021 Enhancement of Umbilical Cord Mesenchymal Stem Cell Therapeutic Activity by Stimulators of T Regulatory Cells and/or Cells Expressing CD73

https://therapeuticsolutionsint.com/therapeutic-solutions-international-identifies-and-files-patent-on-novel-mechanism-of-action-of-its-fda-phase-iii-cleared-jadicell-treatment-of-covid-19-and-delta-variant-2/

Disclosed are means, compositions of matter and protocols useful for treatment of COVID-19 and/or other inflammatory pathologies through stimulation of T regulatory cells and/or T cells expressing CD73 using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment dosage of JadiCells needed to treat a patient is determined by the increase of T regulatory cells and/or CD73 expressing cells that are increased in number and/or activity subsequent to a test dose of JadiCells. In another embodiment stimulators of T regulatory cells and/or CD73 expressing T cells are utilized together with JadiCells in order to augment therapeutic activity. In some embodiments administration of JadiCell is performed with low dose interleukin-2 as a treatment for COVID-19 or other inflammatory related pathologies.

08-11-2021 Induction of Neurogenesis using Umbilical Cord Derived Mesenchymal Stem Cells and Derivatives Thereof

https://therapeuticsolutionsint.com/therapeutic-solutions-international-reports-superior-neurogenesis-induction-in-animal-model-of-viral-induced-cognitive-dysfunction-compared-to-other-stem-cell-types/

Disclosed are means, compositions of matter and protocols useful for treatment of neurological dysfunctions through stimulation of adult neurogenesis using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment viral induced neuropathy is reduced by administration of JadiCells to stimulate neurogenesis. In another embodiment the neurogenic activity of selective serotonin reuptake inhibitors is enhanced by administration of JadiCells. In some embodiments administration of JadiCell exosomes, conditioned media, microvesicles and/or apoptotic bodies is utilized to stimulate neurogenesis.

07-06-2021 Treatment of Parkinson’s Disease by Immune Modulation and Regenerative Means

https://therapeuticsolutionsint.com/therapeutic-solutions-international-patents-modified-stemvacs-dendritic-cell-immunotherapy-to-suppress-parkinsons-disease-in-animal-model/

Disclosed are means, methods and compositions of matter for treatment Parkinson’s Disease through concurrent immune modulation and regenerative means. In one embodiment Parkinson’s Disease is treated by augmentation of T regulatory cell numbers and/or activity while concurrently providing regenerative cells such as mesenchymal stem cells, and/or dopamine secreting cells. In one embodiment administration of immunoglobulins such as IVIG together with low dose interleukin-2 and/or low dose naltrexone is disclosed as a preparatory means prior to administration of therapeutic cells such as stem cells. Other therapeutic means utilized in an adjuvant manner are also provided for hormonal rebalancing, transcranial magnetic stimulation, and deep brain stimulation.

05-21-2021 Lithium as a Monotherapy and/or Stem Cell Adjuvant Therapy for Pulmonary Fibrosis

https://therapeuticsolutionsint.com/therapeutic-solutions-international-develops-novel-stem-cell-based-therapy-to-reduce-lung-scarring-potential-solution-to-post-covid-19-lung-deterioration/

Disclosed are compositions of matter, therapeutics, and protocols useful for reduction and/or reversion of pulmonary fibrosis. In one specific embodiment lithium chloride is administered together with a regenerative cell in a patient suffering from, or at risk of pulmonary fibrosis. In one embodiment said lithium chloride is administered as an adjuvant to a regenerative therapy, wherein said regenerative therapy is a gene therapy, a protein therapy, a cell therapy, or a tissue transplant. In one embodiment lithium chloride, or a salt thereof is utilized alone, or with a regenerative means, to evoke preservation and/or elongation of telomere length in pulmonary tissue. In one embodiment the invention teaches administration of umbilical cord mesenchymal stem cells (MSC) and/or products derived from said cells in order to induce an inhibition of natural or pathological reduction of telomere length, to preserve telomere length or to enhance telomere length. In one embodiment the MSC described in the invention as useful are umbilical cord derived MSC.

10-27-2020 Protection/Regeneration of Neurological Function by Endothelial Protection/Rejuvenation using Stem Cells for Treatment of Conditions such as Chronic Traumatic Encephalopathy and Schizophrenia

https://therapeuticsolutionsint.com/therapeutic-solutions-international-identifies-new-mechanism-of-mesenchymal-stem-cell-treatment-of-brain-injury-2/

Disclosed are therapeutic compounds, protocols, and compositions of matter useful for treatment of neurological conditions. In one embodiment the invention teaches the treatment of chronic traumatic encephalopathy (CTE) through protecting/regenerating the endothelial by administration of cells such as stem cells. In one embodiment stem cells are administered in order to protect the endothelium from apoptosis and to preserve the blood brain barrier. In another embodiment stem cells are administered together with endothelial progenitor cells in order to regenerate neural endothelium. In other embodiments preservation of brain integrity in conditions of degeneration is accomplished by administration of stem cells and/or endothelial cells.